Peptide-based delivery to bone
详细信息 查看全文
- 作者：Kazuhiro Aoki ; Neil Alles ; Niroshani Soysa ; Keiichi Ohya
- 关键词：RANKL (receptor activator of NF-¦ÊB ligand) ; Antagonist ; Bone resorption inhibitory peptide ; Bone formation stimulatory peptide ; Cholesterol-bearing pullulan (CHP) nanogel ; BMP ; Collagen ; Thrombin ; Bone-targeting peptide ; Half-life ; Stability
- 刊名：Advanced Drug Delivery Reviews
- 出版年：2012
- 出版时间：September, 2012
- 年：2012
- 卷：64
- 期：12
- 页码：1220-1238
- 全文大小：1539 K
文摘
Peptides are attractive as novel therapeutic reagents, since they are flexible in adopting and mimicking the local structural features of proteins. Versatile capabilities to perform organic synthetic manipulations are another unique feature of peptides compared to protein-based medicines, such as antibodies. On the other hand, a disadvantage of using a peptide for a therapeutic purpose is its low stability and/or high level of aggregation. During the past two decades, numerous peptides were developed for the treatment of bone diseases, and some peptides have already been used for local applications to repair bone defects in the clinic. However, very few peptides have the ability to form bone themselves. We herein summarize the effects of the therapeutic peptides on bone loss and/or local bone defects, including the results from basic studies. We also herein describe some possible methods for overcoming the obstacles associated with using therapeutic peptide candidates.